Study Evaluating Intravenous CMD-193 in Subjects With Advanced Malignant Solid Tumors

Phase 1 Dose-Escalation Study of Intravenous CMD-193 in Subjects With Advanced Malignant Solid Tumors

The primary purpose of this study is to evaluate the safety, tolerability, and maximum tolerated dose (MTD) of CMD-193 administered intravenously (IV) to subjects with advanced malignant tumors. The secondary purpose is to obtain preliminary information on the pharmacokinetics and antitumor activity of IV CMD-193.

Inclusion Criteria:

• Malignant solid tumor progressed, or no standard treatment available
• Tumor expression of Lewis Y antigen

Exclusion Criteria:

• Cancer therapy within 28 days before enrollment
• Pregnant or breastfeeding women
• Unstable or serious concurrent medical conditions